Amy Wang

Amy (Zichun) Wang, Ph.D., currently serves as Executive Director at Medicilon Inc. since May 2025, following a position as Senior Director at ChemPartner managing the Cell Biology and Immunology/Inflammation group from March 2023 to April 2025. Previously, Amy held roles as Principal Scientist at FogPharma and R&D Senior Scientist at Farcast Biosciences, overseeing translational research collaborations. Furthermore, Amy contributed to drug discovery efforts as a Scientist and Senior Scientist at Eisai US, focusing on high-content screening platforms and cancer immunology. Earlier experiences include a Scientist role at MGI Pharma, developing therapeutic vaccines, a Research Fellow position at Harvard Medical School studying SIV infection mechanisms, and a Visiting Fellow role at NINDS/NIH identifying shared MHC elements for T-cell receptors. Academic credentials include a Ph.D. in Immunology from the National Institute of Virology in Beijing, a Master's in Molecular Biology, and a Bachelor's in Biochemistry, both from Shanxi University.